Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors | Synapse

June 1, 2021Open Access

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Our data show that CDKN2A GAs were associated with reduced benefit from ICI therapy in urothelial carcinoma as well as changes in the tumor-immune microenvironment.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Adib et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcca0fc099bcfdbb133a73 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-21-0575

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comprehensive molecular characterization of gastric adenocarcinoma2014 · 6,521 citations
2Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)2017 · 6 citations
3Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations2020 · 31 citations
4Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors2020 · 79 citations
5A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma2019 · 76 citations